P31 Genetic Profile in NSLC Biopsy
Background: Substantial progress has been made in the characterization of the molecular abnormalities in NSCLC tumors such as activations of oncogenes by mutations, translocations and amplifications, which are being used as molecular targets and predictive biomarkers. The aim of present work was to determine the frequency of molecular alterations in EGFR and gene fusion ALK and to assess associations with age, gender and tobacco habits in our Caucasian and Hispanic to decide the adequate treatment. Method: 115 small biopsies and resection specimens of patients (pts) with NSCLC Adenocarcinoma (AC) were studied during the period 2014 -2017. Histopathology type, Immunohistochemistry (IHC) characteristics as well as molecular profile were analyzed. EGFR mutation was studied by therascreen kit, PCR, in order to detect genetic alterations in exons 18, 19, 20 and 21. (Fig. 1 ) ALK translocations were analyzed by FISH (Vysis-Break Apart, Abbott) and IHC (clon D5F3, ventana, Roche). (Fig. 2) . Molecular profiles were correlated with different clinical variables (age, gender, and tobacco habits). Results: 83% of subjects had smoking habit and this pattern was even significantly associated with gender (70% and 92% for women and men respectively, p¼0.003). 76% the subjects were older than 56 years, having similar distributions between sexes (p¼0.183): mean (standard deviation) equal to 60.8(1.37) years old for women and 63.4(1.1), for men. 26 pts (23 %), 11 men and 15 women expressed EGFR alterations which were associated with gender (p¼0.020, Fig. 4 ). Women had more chance of having positive alterations of the gene (OR 2.82, 95CI:1.15-6.91). Figure 5 shows how women have more greater predicted probabilities for positive EGFR than men, adjusting by smoking status. Age and smoking habit of patients did not show significant effects (p¼0.61, and p¼0.105, respectively). Figure 6 illustrates the age distributions by EGFR and ALK categories. We identified 3 pts (3%) with fusion gene EML4-ALK which were not related to sex (p¼0.305), age (p¼0.859) and smoking habit (p¼0.631). Even though this analysis was performed stratifying by sex, the associations between AKL and covariates were not significant. Conclusion: These results showed a comparable frequency in EGFR mutations and ALK gene fusion translocation to the data published in western population. These data allow an adequate diagnosis and appropriate therapy. Keyword: lung cancer Background: Despite recent progress in diagnostic and oncology therapy, lung cancer constitutes the leading cause of cancer-associated mortality worldwide, with approximately 85% of lung cancer cases being nonesmall cell lung cancer (NSCLC) histological type. The study of epidermal growth factor receptor (EGFR) gene mutational profile in nonesmall cell lung cancer patients has a special clinical significance in the selection of patients for tyrosine-kinase inhibitor therapy. The aim of this study was to identify the frequency and spectrum of EGFR mutations in a cohort of Moroccan patients with lung cancer using the ADx-ARMS technology. Method: We performed a retrospective study by processing 164 cases of NSCLC patients recruited between March 2015 and March 2018. Using the DNA extracted from the formalin-fixed paraffin-embedded FFPE tissue, we attempted to identify somatic mutations in exons 18 to 21 of the tyrosine-kinase "TK" domain of EGFR gene. We evaluated EGFR mutations using High Resolution Melt (HRM) polymerase chain reaction (PCR) and real time PCR "ADx-ARMS technology" for results confirmation. Results: Among the positive mutant cases, the resulting mutations were as follows: 70% of patients have a deletion in exon 19, 10% in exon 21(L858R), 10% in exon 20 (6.7% T790M and 3.3% S768L) and 10% in exon 18 (G719A/C). The EGFR mutations were more frequent among males compared to females (51,7% and 48,3% respectively), all of the positive patients with EGFR mutations were adenocarcinoma (ADK) and 37,9%% of them were smokers. Conclusion: The presented method can be implemented at the laboratories to identify the most frequent EGFR mutations that are important for targeted therapy of advanced lung cancer patients. Background: Small cell lung cancer (SCLC) accounts for about 10%-15% of the total number of lung cancer and with a poor outcome. Especially in extensive-stage (ED) small cell Lung Cancer, the 5-year survival rate is less than 5%. To improve the survival outcome, a number of therapeutic approaches have been tried, such as dose dense chemotherapy, high-dose chemotherapy, maintenance therapy and consolidation chemotherapy. However, the result was of no proven benefit. Patients with a lower pretreatment circulating VEGF levels were more likely to respond to chemotherapy compared to those with higher levels of VEGF. The results from these studies suggest that VEGF may be linked to overall poor outcome in SCLC. Therefore, inhibition of VEGF represents a rational therapeutic strategy for evaluation in SCLC. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Although there have been few studies of small cell Lung Cancer treated with apatinib so far, a retrospective study showed that apatinib exhibits modest activity and acceptable toxicity for the heavily pretreated patients with extensive-stage SCLC. The disease control rate was 81.8%. However, is there a benefit in survival of apatinib as maintenance therapy in extensive-stage SCLC is unclear. Therefore, the aim of this study was to analyze the efficacy and safety of apatinib as maintenance therapy in extensive-stage SCLC. Method: Retrospective analysis of 23 cases extensive-stage SCLC that admitted to The Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy, received apatinib 250mg per day until disease progression or unacceptable toxicity occurs. We analyzed the median progression-free survival (PFS), median Overall survival (OS) and safety. Results: Of 23 enrolled patients,1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95%CI,3.63 to 4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95%CI,7.20 to 9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95%CI,5.51 to 19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95%CI,9.86 to 24.14 months). The most frequent treatmentrelated adverse events were hand-foot syndrome (43.5%, 10/23), secondary hypertension (30.4%, 7/23). Fatigue, proteinuria, nausea, oral mucositis were 17.4%, 13.0%, 13.0%, 8.7%, respectively. Hematologic toxicity includes thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). Main grade 3 or 4 toxicities were hand-foot syndrome (8.7%, 2/23), and hypertension (4.3%, 1/23). Conclusion: Maintenance apatinib was safe and achieved encouraging PFS and OS in extensive-stage SCLC. Keywords: small cell lung cancer, apatinib, maintenance therapy, extensive-stage
